Sarepta Therapeutics (NASDAQ:SRPT) has been given a $75.00 target price by analysts at HC Wainwright in a research note issued to investors on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 28.07% from the stock’s current price.
A number of other equities analysts also recently issued reports on SRPT. Robert W. Baird reaffirmed a “buy” rating and issued a $101.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, October 17th. Oppenheimer reaffirmed a “buy” rating and issued a $76.00 price target on shares of Sarepta Therapeutics in a report on Wednesday, December 27th. BidaskClub downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Royal Bank of Canada assumed coverage on Sarepta Therapeutics in a report on Monday, January 22nd. They issued an “outperform” rating for the company. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $77.00 price target on shares of Sarepta Therapeutics in a report on Friday, January 19th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and seventeen have given a buy rating to the company’s stock. Sarepta Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $64.65.
Sarepta Therapeutics (NASDAQ SRPT) traded up $3.42 during mid-day trading on Monday, hitting $58.56. 1,499,685 shares of the company were exchanged, compared to its average volume of 1,800,000. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52. Sarepta Therapeutics has a 12-month low of $26.26 and a 12-month high of $68.90. The stock has a market capitalization of $3,780.00, a price-to-earnings ratio of -28.71 and a beta of 1.49.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Hall Laurie J Trustee lifted its holdings in shares of Sarepta Therapeutics by 2,430.8% during the fourth quarter. Hall Laurie J Trustee now owns 3,290 shares of the biotechnology company’s stock worth $224,000 after purchasing an additional 3,160 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Sarepta Therapeutics by 39.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 977 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $217,000. Aperio Group LLC acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $219,000. Finally, Legato Capital Management LLC acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $234,000. 82.41% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Sarepta Therapeutics (SRPT) Given a $75.00 Price Target at HC Wainwright” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2018/02/12/sarepta-therapeutics-srpt-given-a-75-00-price-target-at-hc-wainwright.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.